Lupin Ltd

- No explicit mention of any immediate new fundraising through debt or equity in the document. - Current net debt of the company is virtually zero, indicating a strong cash surplus position. - The company has strong ability to raise funds for acquisitions if needed. - Capital allocation policy includes a debt-to-EBITDA ratio target of around 2:1. - Debt capacity is estimated at about INR 10,000 - 11,000 crores considering EBITDA of INR 5,000 - 5,500 crores. - Future capital spending will prioritize India and specialty businesses, with strict financial returns (20% expected) and payback periods (4-6 years). - For adjacencies beyond the current scope, the company may involve private equity or strategic partners instead of increasing its own capital. - Overall, the company plans disciplined capital use with guardrails but has capacity for future debt-funded growth or acquisitions.

- Annual capital expenditure has averaged INR 500-700 crores over the last 4-5 years, mainly for maintenance capex and some expansion in biosimilars, injectables, and related areas. (Ramesh Swaminathan, p.31) - FY25 capex shown as INR 1600 crores includes acquisitions and intangibles (e.g., Medisol acquisition). Cash flow capex figure is after accounting for these. (Ramesh Swaminathan, p.31) - Future capital allocation focuses on specialty and India regions with strict guardrails: Debt to EBITDA around 2:1, expected return around 20%, and payback period between 4-6 years per project. (Ramesh Swaminathan, p.28-29) - R&D spend to increase 10-15% next year, particularly on complex products (biosimilars, inhalation, injectables, 505(b)(2)s, specialty). Capex supports complex generics and specialty pipelines. (p.25, p.31) - Investments continue in expanding US and Europe facilities, with potential for new US sites if incentives arise. (p.21)

- Lupin aims for double-digit growth in revenues and volumes across markets, targeting 20-30% growth ahead of market, where the market grows at 6-8%. (Page 28) - India business targets 1.2-1.3 times market growth with double-digit growth driven by chronic therapies, new product launches, and expanded reach including extra urban markets. (Pages 13, 29) - Continued robust growth expected in complex generics and specialty, particularly in the US and Developed Markets, leveraging a strong product pipeline and new launches like Tolvaptan, Mirabegron, and Spiriva®. (Pages 21, 31) - Growth in biosimilars, injectables, respiratory, oncology, and GI therapy areas projected. (Pages 10, 13, 31) - Emerging markets such as South Africa, Philippines, Mexico, and Brazil expected to grow strongly with new product launches and portfolio expansion. (Page 14) - R&D investments to increase by 10-15% annually to support future pipeline growth. (Page 31)

- Expectation of margin improvement continuously driven by a strong product pipeline and cost efficiency initiatives (Page 21). - EBITDA margins have grown steadily, with FY25 projected at ~23.7%, and an adjusted margin close to 26% excluding certain expenses (Pages 18-19). - Increasing contribution from complex generics and specialty products expected to support earnings growth beyond FY26 (Page 31). - R&D spend to rise by 10-15% with a focus on complex products, supporting future margin and profit growth (Page 25). - Double-digit revenue growth expected in core markets (India, US) with specialty and complex generics expanding margins (Pages 13, 31). - Adjacent businesses anticipated to become EBITDA positive by FY27, contributing to overall profit growth (Page 14). - Overall earnings growth supported by sustained revenue momentum, expanding product pipeline, and margin expansion initiatives.

- Lupin has more than 100 products pending in the pipeline for approval in the US market. - The pending pipeline addresses a market size of close to USD 150 billion. - Key recent approvals include Mirabegron, Spiriva®, Pred Forte®, and Tolvaptan, indicating strong momentum. - CDMO/CRDMO business is evolving with additional capacity available, and the company is building a commercial and project management team to scale this. - The trade generics subsidiary is building its funnel, expected to generate meaningful revenues in the next two years. - The company remains focused on timely injectable product launches, expecting approvals between July-August for key products like Glucagon and Victoza®, and within a couple of months for Risperidone.